問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Far Eastern Memorial Hospital

Recruiting

List

147Cases

2020-01-01 - 2026-06-30

Phase II/III

Active
A Phase 2/3 Study to Evaluate the Safety and Efficacy of Long Acting Capsid Inhibitor GS-6207 in Combination with an Optimized Background Regimen in Heavily Treatment Experienced People Living with HIV-1 Infection with Multidrug Resistance

  • Condition/Disease

    Heavily Treatment Experienced People Living with HIV-1 Infection

  • Test Drug

    Lenacapavir (LEN: previously referred to as GS-6207)

Participate Sites
5Sites

Not yet recruiting3Sites

Recruiting2Sites

2024-05-01 - 2028-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2024-04-15 - 2033-12-31

Phase III

Active
A Randomized, Open-label, Phase 3 Study of MK-2870 vs. Platinum Doublets in Participants With EGFR-mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors

  • Condition/Disease

    Non-small Cell Lung Cancer (NSCLC)

  • Test Drug

    injection

Participate Sites
12Sites

Not yet recruiting11Sites

Recruiting1Sites

2017-01-22 - 2023-12-22

Phase III

Active
A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Ulcerative Colitis

  • Condition/Disease

    Ulcerative Colitis

  • Test Drug

    Filgotinib

Participate Sites
13Sites

Recruiting9Sites

Terminated3Sites

邱正堂
Linkou Chang Gung Medical Foundation

2024-01-01 - 2027-02-28

Phase II/III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting2Sites

Recruiting4Sites

2024-07-30 - 2028-09-30

Phase III

Active
EASi-HF Preserved – A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) ≥40%

  • Condition/Disease

    heart failure

  • Test Drug

    cpasule

Participate Sites
10Sites

Recruiting10Sites

2023-03-01 - 2027-02-28

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
16Sites

Recruiting16Sites

2021-01-04 - 2026-03-31

Others

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2021-12-31 - 2026-12-31

Phase III

Active
A Pivotal Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of DMX-200 in Patients With Focal Segmental Glomerulosclerosis (FSGS) Who Are Receiving an Angiotensin II Receptor Blocker (ARB)

  • Condition/Disease

    FSGS

  • Test Drug

    膠囊劑

Participate Sites
8Sites

Recruiting8Sites

2021-03-01 - 2026-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

1 5 6 7 8 9 15
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB